Dana-Farber Cancer Institute Enhances Liquid Biopsy Techniques Using n6's iconPCR System

Advancements in Liquid Biopsy at Dana-Farber Cancer Institute



The Dana-Farber Cancer Institute has made significant strides in liquid biopsy research by integrating the innovative iconPCR™ technology into its Molecular Biology Core Facilities (MBCF). This development focuses on enhancing the reliability and efficiency of sequencing cell-free DNA (cfDNA), especially for targeted assays in cancer research. The incorporation of the icon96 system, developed by n6 Tec, Inc., represents a groundbreaking approach to low-input sequencing workflows.

Reducing Variability in Library Yield


The recent adoption of the n6 iconPCR system allows for the efficient processing of cfDNA samples, ensuring that even the smallest amounts of DNA — as low as 1 ng — can yield consistent results. Traditionally, low-input cfDNA sequencing is fraught with challenges, particularly when rare tumor variants exist at frequencies below 1%. With the n6 technology, variability in library yields dropped dramatically from 54% to only 8%, showcasing the potential for improved accuracy in detecting critical genomic alterations.

Zach Herbert, the Director of the MBCF at Dana-Farber, emphasized the importance of precision in handling these precious samples by stating, "Our investigators bring us precious samples where every molecule counts. With icon96, we can see the amplification path of every sample and stop each reaction where it should stop, so low-input cfDNA libraries come out uniform and ready for capture."

Innovative Workflow Enhancements


The integrated workflow developed at Dana-Farber employs a combination of dual-unique molecular identifiers (UMIs) for library preparation, specialized amplification on the icon96, followed by a hybrid capture mechanism and duplex sequencing. This sophisticated setup facilitates the simultaneous processing of samples with varying input amounts in a single run, eliminating the need for manual adjustments.

In rigorous testing using reference-standard materials, the MBCF was able to reliably detect genetic variants at a low threshold of 0.5% allele frequency, confirming the capability of the iconPCR technology to maintain a 200x target coverage at minimal DNA inputs.

Efficient Sample Normalization


The capacity to normalize samples ranging from 2 ng to 25 ng within a single workflow run is another notable advancement. This capability presents a significant leap in operational efficiency, allowing researchers to process diverse patient-derived samples without compromising data quality. Following the introduction of the icon96 system, the on-target capture rates exceeded 90% across multiple sample sets.

Pranav Patel, CEO and co-founder of n6, further highlighted the advantages of this innovative approach: "When every molecule matters, the workflow should adapt to each sample rather than force an entire batch through the same rigid process. Dana-Farber's work demonstrates that treating each sample individually protects the underlying biological signal while simplifying operations."

A Major Step for Liquid Biopsy Research


This collaboration between Dana-Farber and n6 Tec showcases a transformative step forward in cfDNA sequencing technology. Given the technically demanding nature of liquid biopsies and the critical information they hold regarding cancer diagnosis and monitoring, the improvements in yield consistency and accuracy are poised to have significant implications for clinical applications.

For further insights on the iconPCR technology and its applications in low-input sequencing, interested parties can visit n6tec.com. Additionally, details regarding the Dana-Farber MBCF cfDNA services can be accessed through their official webpage. This advancement not only highlights the evolving landscape of cancer research but also cements Dana-Farber's commitment to leveraging cutting-edge technology for the benefit of patient outcomes.

Ultimately, the integration of the latest innovations signifies a promising future for the realm of liquid biopsy, potentially leading to earlier detection and better treatment strategies for various forms of cancer.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.